Ardelyx, Inc. Stock Hits Day Low of $5.55 Amid Price Pressure

Ardelyx, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced significant volatility today, with the stock hitting an intraday low of USD 5.55. The company has seen a notable decline of -14.69% as of February 23, 2026. In terms of performance metrics, Ardelyx has underperformed relative to the S&P 500 across various time frames. Over the past week, the stock has dropped -16.3%, while the S&P 500 has gained 1.07%. The one-month performance shows a decline of -26.0% for Ardelyx, contrasting with a modest increase of 1.66% for the broader market. Year-to-date, the stock is down -1.37%, while the S&P 500 has risen by 0.94%. Despite a positive return of 13.64% over the past year, Ardelyx's performance still lags behind the S&P 500's return of 12.95%. Financial indicators reveal a pre-tax profit of USD -19.08 million, reflecting a decline of -45.1%, and a net profit of the same amount, down -42.39%. The company’s debt-to-equity ratio stands at -0.36, and it has not issued dividends, further highlighting its current financial challenges.